National Institutes of Health, National Institute of Allergy and Infectious Diseases: EMBARGOED FOR RELEASE Tuesday, Dec. 16, 1997 (301) 402-1663 4:00 p.m. EST jbowersox@nih.gov
John Bowersox; (301) 402-1663 - jbowersox@nih.gov
Two studies supported by the National Institute of Allergy and Infectious Diseases (NIAID) provide important new information about the HIV/AIDS epidemic in India , the country with the single largest number of HIV-infected persons in the world. One study identifies risk factors and describes clinical symptoms associate
National Institutes of Health, National Institutes of Allergy and Infectious Disease. EMBARGOED FOR RELEASE Thursday, Nov. 13, 1997 4:00 p.m. Eastern Time gfolkers@nih.gov
Greg Folkers (301) 402-1663 gfolkers@nih.gov
HIV persists and can replicate in patients who have no detectable virus in their blood as a result of combination antiretroviral therapy, according to a new report from researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and their colleagues. Our findings indicate that an inducible reservoi
National Institutes of Health, National Institute of Allergy and Infectious Diseases--Monday, Sept. 15, 1997
Greg Folkers (301) 402-1663 gfolkers@nih.gov
A recently described genetic mutation does not fully explain why a small proportion of people infected with the human immunodeficiency virus (HIV) remain completely well for a decade or more, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID). Instead, the researchers say, t
NIH NEWS: National Institutes of Health, National Institute of Allergy and Infectious Diseases. EMBARGOED FOR RELEASE Laurie K. Doepel Thursday, Sept. 4, 1997 5:00 p.m. Eastern Time
Laurie K. Doepel (301) 402-1663 ldoepel@nih.gov
National Institute of Allergy and Infectious Diseases (NIAID) grantees at Yale University have converted a common livestock virus into a Trojan horse that selectively targets HIV-infected cells and then destroys them. As reported Sept. 5 in the journal Cell, this strategy effectively controlled HIV infection in laborat
NIAID NEWS: National Institutes of Health National Institute of Allergy and Infectious Diseases - EMBARGOED FOR RELEASE Wednesday, July 30, 1997, 5:00 p.m. Eastern Time
John Bowersox (301) 402-1663 jbowersox@nih.gov
HIV-infected patients at high risk for tuberculosis (TB) but without confirmed TB infection do not benefit from preventive treatment with a front-line TB drug, a study supported by the National Institute of Allergy and Infectious Diseases (NIAID) has found. The study is reported in the July 31, 1997 issue of The New En
NIH NEWS: National Institutes of Health, National Institute of Allergy and Infectious Diseases - FOR RELEASE Thursday, June 26, 1997 9:00 a.m. Eastern Time
Cheryl Parrott, (301) 402-1663, cparrott@nih.gov
An ambitious new program funded by the National Institute of Allergy and Infectious Diseases (NIAID) focuses on innovative ways to study how HIV-1 causes disease in adults. Scientists at six research units will use interventions, such as highly active antiretroviral therapy given in the acute and early phases of infect
NIH NEWS: National Institutes of Health, National Institute of Allergy and Infectious Diseases - FOR RELEASE Thursday, June 26, 1997
Laurie K. Doepel, (301) 402-1663 - ldoepel@nih.gov
Initial therapy using zidovudine ( AZT ) combined with either lamivudine ( 3TC ) or didanosine (ddI) is far more effective at staving off disease progression or death in children with symptomatic HIV disease than using ddI alone, according to a large multicenter study supported by the National Ins
National Institutes of Health, National Institute of Allergy and Infectious Diseases FOR IMMEDIATE RELEASE - Monday, June 16, 1997 (301)
John Bowersox (301) 402-1663 / jbowersox@nih.gov
In two of the most definitive studies of prognostic markers for HIV disease published to date, investigators supported by the National Institute of Allergy and Infectious Diseases (NIAID) have found that combining HIV RNA measurements with CD4+ T cell counts provides the most accurate prediction of disease progression
National Institutes of Health, National Institute for Allergy and Infectious Diseases. FOR RELEASE - Wednesday, May 21, 1997
Cheryl Parrott (301) 402-1663 cparrott@nih.gov
Thalidomide effectively heals severe mouth and throat ulcers in people with HIV infection, according to a study supported by the National Institute of Allergy and Infectious Diseases (NIAID) and reported in the May 22, 1997, issue of The New England Journal of Medicine. For the many patients with HIV infection who suff
National Institutes of Health, National Institute of Allergy and Infectious Diseases - FOR RELEASE Wednesday, May 7, 1997
Cheryl Parrott (301) 402-1663 cparrott@nih.gov
The amount of HIV in the blood of perinatally infected infants peaks at 1 to 2 months of age and then declines slowly to level off at 24 months at relatively high concentrations compared to those for an adult, according to a study supported by the National Institutes of Health (NIH). The study was reported in the May 8
Prepared by: Office of Communications National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892 Public Health Service U.S. Department of Health and Human Services May 1997
The face of AIDS in the United States is changing. Minorities, primarily African Americans and Hispanics, now constitute 54 percent of the more than 500,000 cases of AIDS reported since the epidemic began in 1981. African Americans and Hispanics are disproportionately affected by AIDS, as illustrated by the following f
Prepared by: Office of Communications National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892 Public Health Service U.S. Department of Health and Human Services May 1997
AIDS--acquired immune deficiency syndrome--was first reported in the United States in 1981 and has since become a major worldwide epidemic. AIDS is caused by the human immunodeficiency virus (HIV). By killing or impairing cells of the immune system, HIV progressively destroys the body s ability to fight infections and
Prepared by: Office of Communications National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892 Public Health Service U.S. Department of Health and Human Services May 1997
The National Institute of Allergy and Infectious Diseases (NIAID) is the principal agency of the U.S. Public Health Service responsible for conducting basic and clinical research on acquired immunodeficiency syndrome (AIDS), and the human immunodeficiency virus (HIV). NIAID s efforts cover five broad scientific areas:
National Institutes of Health, National Institute of Allergy and Infectious Diseases - FOR RELEASE Tuesday, April 29, 1997
Greg Folkers (301) 402-1663 folkers@nih.gov
The immune system s army of CD4+ T cells not only declines in overall size during the course of HIV disease, but also becomes progressively less diverse as specific CD4+ T cells programmed to fight different invaders are lost, according to researchers at the National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Thursday, April 3, 1997
Patricia Randall (301) 402-1663 prandall@nih.gov
A large two-year study supported by the National Institute of Allergy and Infectious Diseases (NIAID) showed that vaginal contraceptive film containing a commonly used spermicide had no effect on transmission of HIV/AIDS, gonorrhea or chlamydia infections when provided as part of an overall HIV/STD prevention program.
Prepared by: Office of Communications National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892 Public Health Service U.S. Department of Health and Human Services April 1997
Overview The number of women with HIV and AIDS in the United States is steadily rising. From 1985 to 1996, the proportion of reported U.S. AIDS cases occurring among women increased from 7 percent to 20 percent. HIV infection is now the third leading cause of death among women ages 25 to 44 and the leading cause of dea
Prepared by: Office of Communications National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892 Public Health Service U.S. Department of Health and Human Services April 1997
NIAID supports clinical trials networks through the NIAID Division of AIDS to identify effective therapies for men, women and children with HIV infection. The Adult AIDS Clinical Trials Group (ACTG) is a network of 30 sites based at major academic institutions with the ability to carry out sophisticated large-scale res
Prepared by: Office of Communications National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, MD 20892 Public Health Service U.S. Department of Health and Human Services April 1997
Overview The National Institute of Allergy and Infectious Diseases (NIAID) has a lead role in research devoted to children infected with the human immunodeficiency virus (HIV), the virus that causes the acquired immunodeficiency syndrome (AIDS). NIAID-supported researchers are developing and refining treatments to prol
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Monday, March 24, 1997
Laurie K. Doepel (301) 402-1663 doepel@nih.gov
As reported in the April issue of the Journal of Infectious Diseases, investigators at the National Institutes of Health (NIH) have found that self-administered injections of the immune system protein interleukin-2 ( IL-2 ) can produce prolonged, dramatic increases in levels of CD4+ T cells in some people infected with
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Wednesday, March 5, 1997
John Bowersox (301) 402-1663 jbowersox@nih.gov
Acting on the recommendation of an expert advisory panel, the National Institute of Allergy and Infectious Diseases (NIAID) has unveiled a new grant program designed to speed the pace of AIDS vaccine discovery and development. Called the INNOVATION Grant Program for Approaches in HIV Vaccine Research, the new initiativ
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Tuesday, Feb. 25, 1997 Noon Eastern Time
Laurie K. Doepel (301) 402-1663 doepel@nih.gov
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded 23 four-year grants to continue the work of the Pediatric AIDS Clinical Trials Group (ACTG). A nationwide clinical trials network, the group evaluates improved strategies to prevent infants of infected mothers from acquiring HIV in utero or d
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Monday, Feb. 24, 1997
Pat Randall (301) 402-1663
Research supported by the National Institute of Allergy and Infectious Diseases (NIAID) has demonstrated that in patients with advanced HIV disease the combination of a protease inhibitor plus two nucleoside analogue reverse transcriptase inhibitors (RTIs) is significantly more effective in reducing the occurrence of A
National Institutes of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Wednesday, Feb. 19, 1997
James Hadley (301) 402-1663
In the largest asthma study ever completed of children in the inner city, researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID) found a wide variety of factors, rather than one single cause, responsible for the dramatic increase in asthma morbidity. Asthma has been increasing in the
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Wednesday, Feb. 19, 1997
James Hadley (301) 402-1663
Four prominent scientists - including a Nobel Laureate - will present recent research findings that have far-reaching future implications for organ transplantation, autoimmune disease and screening potential drugs to restore immune function. A symposium titled Contemporary Topics in Immunology is scheduled for Friday,
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Saturday, Feb. 15, 1997
John Bowersox (301) 402-1663 jbowersox@nih.gov
Reports that some individuals may be immune to infection with HIV have contributed significantly to the atmosphere of cautious optimism that currently surrounds AIDS research. In a symposium on Saturday, February 15, at the annual meeting of the American Association for the Advancement of Science (AAAS), leading resear
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Sunday, Jan. 26, 1997 9:30 a.m. Eastern Time
Laurie K. Doepel (301) 402-1663 doepel@nih.gov
In-depth studies of immune function in people with moderately advanced HIV disease who were treated for three months with an antiretroviral drug cocktail show that immunity can be partially restored, according to preliminary results from AIDS Clinical Trials Group (ACTG) 315, supported by the National Institute of Alle
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Thursday, Jan. 23, 1997
John Bowersox (301) 402-1663 jbowersox@nih.gov
Within the past year, a steady succession of studies have implicated molecules known as chemokine receptors as the long-sought co-factors that enable HIV to enter and infect immune system cells. Many scientists believe these findings could point the way toward more effective treatment and prevention strategies for HIV/
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR RELEASE Wednesday, Jan. 22, 1997
Greg Folkers (301) 402-1663 Folkers@nih.gov
During this week s Fourth Conference on Human Retroviruses and Related Infections in Washington, D.C., scientists from the Laboratory of Immunoregulation (LIR) of the National Institute of Allergy and Infectious Diseases (NIAID) will present important new findings that help illuminate the HIV disease process and the co
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR IMMEDIATE RELEASE Thursday, Jan. 16, 1997
John Bowersox (301) 402-1663 jbowersox@nih.gov
A National Institute of Allergy and Infectious Diseases intramural research team is co-winner of this year s prestigious American Association for the Advancement of Science (AAAS)-Newcomb Cleveland Prize, awarded to the authors of the best paper published in Science, as judged by the journal s editors. The award-winnin
National Institute of Allergy and Infectious Diseases, National Institutes of Health - FOR IMMEDIATE RELEASE Thursday, Jan. 9, 1997
Greg Folkers (301) 402-1663 folkers@nih.gov
Certain patterns of immune responses to the human immunodeficiency virus (HIV) during the first weeks of infection are highly predictive of an individual s subsequent rate of disease progression, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID) and their colleagues. Our da
This information is designed to support, not replace, the relationship that exists between you and your doctor.